Lantern Pharma (LTRN) Restructuring Costs (2020 - 2023)

Lantern Pharma (LTRN) has reported Restructuring Costs for 4 consecutive years, with $42000.0 the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Restructuring Costs rose 7.69% year-over-year to $42000.0; the trailing twelve-month figure through Mar 2023 stood at $147000.0 (up 3.52% YoY), and the FY2022 full-year result was $144000.0, up 37.14% from the prior year.
• Restructuring Costs rose to $42000.0 in Q1 2023 per LTRN's latest filing, from $36000.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $42000.0 in Q1 2023 and bottomed at $1000.0 in Q3 2020.
• Historically, Restructuring Costs has averaged $25500.0 across 4 years, with a median of $33000.0 in 2022.
• The sharpest annual moves came in 2021 and 2022: Restructuring Costs surged 3700.0% in 2021, then declined 21.05% in 2022.
• Over 4 years, Restructuring Costs stood at $2000.0 in 2020, then jumped by 1800.0% to $38000.0 in 2021, then dropped by 5.26% to $36000.0 in 2022, then advanced by 16.67% to $42000.0 in 2023.
• According to Business Quant data, Restructuring Costs over the past three periods registered $42000.0, $36000.0, and $30000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.